UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | C000000374 |
|---|---|
| Receipt number | R000000468 |
| Scientific Title | A combination of prednisolone, warfarin and dipyridamole for IgA nephropathy with diffuse mesangial proliferation in children. |
| Date of disclosure of the study information | 2006/04/01 |
| Last modified on | 2006/03/27 18:40:48 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A combination of prednisolone, warfarin and dipyridamole for IgA nephropathy with diffuse mesangial proliferation in children.
Acronym
A combination of prednisolone, warfarin and dipyridamole for IgA nephropathy with diffuse mesangial proliferation in children.
Scientific Title
A combination of prednisolone, warfarin and dipyridamole for IgA nephropathy with diffuse mesangial proliferation in children.
Scientific Title:Acronym
A combination of prednisolone, warfarin and dipyridamole for IgA nephropathy with diffuse mesangial proliferation in children.
Region
| Japan |
Condition
Condition
IgA nephropathy in children
Classification by specialty
| Nephrology | Pediatrics |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
We investigate efficacy and safety of a combination of prednisolone, warfarin and dipyridamole for IgA nephropathy with diffuse mesangial proliferation in children.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Disappearance rate of proteinuria
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
prednisolone+warfarin+dipyridamole for 2 years
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 2 | years-old | <= |
Age-upper limit
| 18 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
1.Newly biopsy proven IgA nephropathy with diffuse mesangial proliferation
2.Aged 2 to 18 years
3.Written informed consent from the patients' parents or legal guardians
Key exclusion criteria
1.Nephrotic syndrome
2.Systemic diseases defined on renal biopsy, clinical features or serology (Henoch-Schönlein nephritis, systemic lupus erythematosus, etc)
3.Medical history of allergy or hypersensitivity reactions to prednisolone, warfarin or dipyridamole
3.Chronic renal dysfunction
4.Active infectious disease
5.Severe liver disfunction
6.History of corticosteroid and immunosupression administration
7.Pregnancy
8.Judged inappropriate for this study by the physicians
Target sample size
20
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Norishige Yoshikawa |
Organization
Wakayama Medical University
Division name
Department of Pediatrics
Zip code
Address
811-1 Kimiidera Wakayama City Wakayama
TEL
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Koichi Nakanishi |
Organization
The Japanese Pediatric IgA Nephropathy of Treatment Study Group
Division name
Department of Pediatrics, Wakayama Medical University
Zip code
Address
811-1 Kimiidera Wakayama City Wakayama
TEL
Homepage URL
Sponsor or person
Institute
The Japanese Pediatric IgA Nephropathy of
Treatment Study Group
Institute
Department
Personal name
Funding Source
Organization
The Kidney Foundation, Japan
Organization
Division
Category of Funding Organization
Non profit foundation
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2006 | Year | 04 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 1998 | Year | 06 | Month | 15 | Day |
Date of IRB
Anticipated trial start date
| 1998 | Year | 08 | Month | 01 | Day |
Last follow-up date
| 2005 | Year | 07 | Month | 01 | Day |
Date of closure to data entry
| 2006 | Year | 07 | Month | 01 | Day |
Date trial data considered complete
| 2006 | Year | 07 | Month | 01 | Day |
Date analysis concluded
| 2006 | Year | 07 | Month | 01 | Day |
Other
Other related information
Management information
Registered date
| 2006 | Year | 03 | Month | 27 | Day |
Last modified on
| 2006 | Year | 03 | Month | 27 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000468
